Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition

Journal of Controlled Release

Volumn 112, Issue 2, 2006, Pages 208-213

  Lamprecht, Alf ^a   Benoit, Jean Pierre ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Cancer; Etoposide; Glioma; Lipid nanocapsules; Multidrug resistance; Nanoparticles; P glycoprotein

Indexed keywords

CONTROLLED DRUG DELIVERY; PROTEINS; SURFACE ACTIVE AGENTS; TUMORS;

ETOPOSIDE; GLIOMA; LIPID NANOCAPSULES; MULTIDRUG RESISTANCE; NANOPARTICLES; P-GLYCOPROTEIN;

CELL CULTURE;

DRUG CARRIER; ETOPOSIDE; GLYCOPROTEIN P; LABRAFAC; LIPID; NANOCAPSULE; NANOPARTICLE; OIL; PHOSPHATIDYLCHOLINE; S75 3; SOLUTOL HS 15; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GLIOMA CELL; INCUBATION TIME; MULTIDRUG RESISTANCE; NEWBORN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; ETOPOSIDE; GLIOMA; LIPIDS; NANOSTRUCTURES; P-GLYCOPROTEIN; RATS;

EID: 33646124502     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.02.014     Document Type: Article

References (32)

1. Stein W.D. Reversers of the multidrug resistance transporter P-glycoprotein. Curr. Opin. Investig. Drugs 3 (2002) 812-817
2. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40 (1997) S13-S19
3. Hu Y.P., Henry-Toulme N., and Robert J. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur. J. Cancer 31A 3 (1995) 389-394
4. Soma C.E., Dubernet C., Bentolila D., Benita S., and Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21 (2000) 1-7
5. de Verdiere A.C., Dubernet C., Nemati F., Soma E., Appel M., Ferte J., Bernard S., Puisieux F., and Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 76 (1997) 198-205
6. de Verdiere A.C., Dubernet C., Nemati F., Poupon M.F., Puisieux F., and Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol. 33 (1994) 504-508
7. Bennis S., Chapey C., Couvreur P., and Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer 30A 1 (1994) 89-93
8. Koukourakis M.I., Koukourakis S., Fezoulidis I., Keledis N., Kyrias G., Archimandritis S., and Karkavistas N. High tumoral accumulation of stealth liposomal doxorubicin (caelyx) in glioblastomas and in metastatic brain tumors. Br. J. Cancer 83 (2000) 1281-1286
9. Hu Y.P., Jarillon S., Dubernet C., Couvreur P., and Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother. Pharmacol. 37 (1996) 556-560
10. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., and Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16 (1999) 1836-1842
11. Fernandez-Urrusuno R., Fattal E., Porquet D., Feger J., and Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol. Appl. Pharmacol. 130 (1995) 272-279
12. Lamprecht A., Bouligand Y., and Benoît J.P. New lipid nanocapsules exhibit sustained release properties for amiodarone. J. Control. Release 84 (2002) 59-68
13. Buckingham L.E., Balasubramanian M., Emanuele R.M., Clodfelter K.E., and Coon J.S. Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int. J. Cancer 62 (1995) 436-442
14. Coon J.S., Knudson W., Clodfelter K., Lu B., and Weinstein R.S. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 51 (1991) 897-902
15. Huet S., Schott B., and Robert J. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. Br. J. Cancer 65 (1992) 538-544
16. Abe T., Hasegawa S., Taniguchi K., Yokomizo A., Kuwano T., Ono M., Mori T., Hori S., Kohno K., and Kuwano M. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer 58 (1994) 860-864
17. Koike K., Abe T., Hisano T., Kubo T., Wada M., Kohno K., and Kuwano M. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Jpn. J. Cancer Res. 87 (1996) 765-772
18. Molinari A., Cianfriglia M., Meschini S., Calcabrini A., and Arancia G. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int. J. Cancer 59 (1994) 789-795
19. Denecke J., Fiedler K., Hacker-Klom U., Molenkamp G., Jürgens H., and Wolff J.E. Multiple drug-resistant C6 glioma cells cross-resistant to irradiation. Anticancer Res. 17 (1997) 4531-4534
20. Yamashima T., Ohnishi T., Nakajima Y., Terasaki T., Tanaka M., Yamashita J., Sasaki T., and Tsuji A. Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma. Exp. Brain Res. 95 (1993) 41-50
21. Saito Y., Nakada Y., Hotta T., Mikami T., Kurisu K., Yamada K., Kiya K., Kawamoto K., and Uozumi T. Cross-resistance patterns in ACNU-resistant glioma sublines in culture. J. Neurosurg. 75 (1991) 277-283
22. Shirazi F.H., Bahrami G., Stewart D.J., Tomiak E., Delorme F., Noel D., and Goel R. A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. J. Pharm. Biomed. Anal. 25 (2001) 353-356
23. McAllister R.V., and Lisk R.J. Polyoxyethylene stearate-colorimetric determination in dilute solutions. Anal. Chem. 23 (1951) 609-610
24. Garrigues A., Nugier J., Ferté J., Orlowski S., and Ezan E. In Vitro Drug Screening Assay for Testing Interaction with P-Glycoprotein Based on its ATPase Activity, 2000 AAPS Annual meeting, Indianapolis, USA (2000)
25. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
26. Buckingham L.E., Balasubramanian M., Safa A.R., Shah H., Komarov P., Emanuele R.M., and Coon J.S. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters. Int. J. Cancer 65 (1996) 74-79
27. Tiberghien F., and Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-cancer Drugs 7 (1996) 568-578
28. Matsumoto Y., Sasaoka N., Tsuchida T., Fujiwara T., Nagao S., and Ohmoto T. Fluorescent dye rhodamine 6G as a molecular probe to study drug resistance of C6 rat glioma cells. J. Neuro-Oncol. 13 (1992) 217-222
29. Vauthier C., Dubernet C., Chauvierre C., Brigger I., and Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkylcyanoacrylate) nanoparticles. J. Control. Release 93 (2003) 151-160
30. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 99 (2004) 259-269
31. Batrakova E.V., Li S., Alakhov V.Y., Miller D.W., and Kabanov A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304 (2003) 845-854
32. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., and Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299 (2001) 483-493